Previous 10 | Next 10 |
Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Jazz Pharmaceuticals' (NASDAQ: JAZZ ) solriamfetol to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstr...
DUBLIN , Nov. 15, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorisation of solriamfetol to impro...
DUBLIN , Nov. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor conferences. Jefferies 2019 London Healthcare Conference in London, UK on Thursday, November 21, 2019 ...
15 abstracts spanning Jazz's hematology/oncology therapeutic area focusing on acute leukemias and complications of stem cell transplantation New sub-analysis of Vyxeos Phase 3 trial data accepted as an oral presentation DUBLIN , Nov. 7, 2019 /PRNewswire/ -- Jazz Pharmaceutica...
Image source: The Motley Fool. Jazz Pharmaceuticals (NASDAQ: JAZZ) Q3 2019 Earnings Call Nov 05, 2019 , 4:30 p.m. ET Operator Continue reading
Jazz Pharmaceuticals plc (JAZZ) Q3 2019 Results Earnings Conference Call November 5, 2019, 04:30 PM ET Company Participants Katherine Littrell - Vice President, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Daniel Swisher, Jr. - President and Chief Operat...
Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q3 results : More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Read more ...
The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2019 Q3 earnings Read more ...
Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q3 Non-GAAP EPS of $4.10 beats by $0.51 ; GAAP EPS of $1.78 misses by $0.32 . Revenue of $537.7M (+14.6% Y/Y) beats by $13.78M . Shares +5.6% . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Stocks on th...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...